Parul Patel, MD
Nephrology · San Francisco, CANPI 1528262870
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.7%), food and beverage and education — rather than concentrated in one kind of arrangement. CSL Behring accounts for 70.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,399 and has fallen 95.0% since, to $120 in 2025.
Across 23 payments — averaging $141.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Sanofi-aventis U.S. LLC$267
- Medtronic$161
- UCB, Inc.$125
- Novo Nordisk$122
- AstraZeneca$100
- plus $174 from 6 others
What the payments were for
- Travel & lodging$1,94660%
- Food & beverage$1,20737%
- Education$1063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $2,310 |
| Sanofi-aventis U.S. LLC | 2 | $267 |
| Medtronic | 2 | $161 |
| UCB, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $122 |
| AstraZeneca | 1 | $100 |
| Dexcom, Inc. | 1 | $89 |
| Veloxis Pharmaceuticals, Inc. | 1 | $31 |
| Eton Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Insulet Corporation | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$267
- MINIMED 780G$140
- Wegovy$122
How this compares
$3,258 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NulojixBelatacept | 13 | $25,098 |
| Tacrolimus | 85 | $19,670 |
| Mycophenolate Mofetil | 85 | $16,088 |
| Cinacalcet Hcl | 12 | $7,715 |
| Valganciclovir Hcl | 56 | $4,482 |
| Clotrimazole | 24 | $3,615 |
| Prednisone | 308 | $1,990 |
| Fluconazole | 12 | $756 |
| Pantoprazole Sodium | 51 | $393 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $290 |
| Losartan Potassium | 37 | $237 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 50 | $233 |
| Hydralazine Hcl | 16 | $209 |
| Carvedilol | 16 | $99 |
| Amlodipine Besylate | 20 | $78 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Francisco
- Meyeon ParkSan Francisco$119K
- Raymond HsuSan Francisco$77K
- Fred LuiSan Francisco$68K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.